title: Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies.
abstract: To examine the impact of type 2 diabetes on direct and indirect costs and to describe the effect of relevant diabetes-related factors, such as type of treatment or glycaemic control on direct costs.
  
  
  
  Bottom-up excess cost analysis from a societal perspective based on population-based survey data.
  
  
  
  9160 observations from 6803 individuals aged 31-96 years (9.6% with type 2 diabetes) from the population-based KORA (Cooperative Health Research in the Region of Augsburg) studies in Southern Germany.
  
  
  
  Healthcare usage, productivity losses, and resulting direct and indirect costs.
  
  
  
  Information on diabetes status, biomedical/sociodemographic variables, medical history and on healthcare usage and productivity losses was assessed in standardised interviews and examinations. Healthcare usage and productivity losses were costed with reference to unit prices and excess costs of type 2 diabetes were calculated using generalised linear models.
  
  
  
  Individuals with type 2 diabetes had 1.81 (95% CI 1.56 to 2.11) times higher direct (€3352 vs €1849) and 2.07 (1.51 to 2.84) times higher indirect (€4103 vs €1981) annual costs than those without diabetes. Cardiovascular complications, a long diabetes duration and treatment with insulin were significantly associated with increased direct costs; however, glycaemic control was only weakly insignificantly associated with costs.
  
  
  
  This study illustrates the substantial direct and indirect societal cost burden of type 2 diabetes in Germany. Strong effort is needed to optimise care to avoid progression of the disease and costly complications.
authors.affiliation: Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.|Institute for Medical Informatics, Biometrics and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Ulrich
authors.affiliation: Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.|German Center for Diabetes Research (DZD), Neuherberg-München, Germany.
authors.forename: Rolf
authors.initials: R
authors.lastname: Holle
authors.affiliation: Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
authors.forename: Margarethe
authors.initials: M
authors.lastname: Wacker
authors.affiliation: Institute for Medical Informatics, Biometrics and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany.
authors.forename: Renee
authors.initials: R
authors.lastname: Stark
authors.affiliation: German Center for Diabetes Research (DZD), Neuherberg-München, Germany.|Faculty of Medicine, Institute of Health Services Research and Health Economics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.|Paul Langerhans Group for Health Services Research and Health Economics, German Diabetes Center at the Heinrich-Heine-University, Leibniz Center for Diabetes Research, Düsseldorf, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Icks
authors.affiliation: Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Thorand
authors.affiliation: Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
authors.forename: Annette
authors.initials: A
authors.lastname: Peters
authors.affiliation: Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.|German Center for Diabetes Research (DZD), Neuherberg-München, Germany.
authors.forename: Michael
authors.identifier: 0000-0001-8775-7417
authors.initials: M
authors.lastname: Laxy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017281:Cost of Illness; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000191:economics*; D005260:Female; D005858:Germany; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D011795:Surveys and Questionnaires
chemical_list: D007328:Insulin
keywords: bottom up approach; direct costs; indirect costs; population-based; type 2 diabetes